{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:16:01Z","timestamp":1793103361827,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010648","name":"Universitaire Ziekenhuizen Leuven, KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.nmd.2025.105397","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T19:16:25Z","timestamp":1748459785000},"page":"105397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Two-year Risdiplam treatment in adults with spinal muscular atrophy: improvements in motor and respiratory function, quality of life and fatigue"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-5119","authenticated-orcid":false,"given":"Louise","family":"Iterbeke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-443X","authenticated-orcid":false,"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.nmd.2025.105397_bib0001","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0002","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2025.105397_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal Muscular atrophy: mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl. Clin. Genet."},{"issue":"8","key":"10.1016\/j.nmd.2025.105397_bib0004","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal Muscular Atrophy: clinical classification and disease heterogeneity","volume":"22","author":"Russman","year":"2007","journal-title":"J. Child Neurol."},{"issue":"3","key":"10.1016\/j.nmd.2025.105397_bib0005","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ene.13534","article-title":"Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134","volume":"25","author":"Wadman","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"18","key":"10.1016\/j.nmd.2025.105397_bib0006","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.nmd.2025.105397_bib0007","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.nmd.2025.105397_bib0008","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.nmd.2025.105397_bib0009","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.nmd.2025.105397_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/1756285618754459","article-title":"Nusinersen for spinal muscular atrophy","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.nmd.2025.105397_bib0011","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2020","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.nmd.2025.105397_bib0012","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.nmd.2025.105397_bib0013","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0014","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12883-024-03562-x","article-title":"Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction","volume":"24","author":"Bjelica","year":"2024","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2025.105397_bib0016","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00415-024-12203-9","article-title":"Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment","volume":"271","author":"Brakemeier","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16099","article-title":"Evaluation of Risdiplam efficacy in 5q spinal muscular atrophy: a systematic comparison of electrophysiologic with clinical outcome measures","volume":"31","author":"Kessler","year":"2024","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2025.105397_bib0018","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.27804","article-title":"Risdiplam in non-sitter patients aged 16\u2009years and older with 5q spinal muscular atrophy","volume":"67","author":"\u00d1ungo Garz\u00f3n","year":"2023","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0019","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-024-03442-0","article-title":"Risdiplam: therapeutic effects and tolerability in a small cohort of 6 adult type 2 and type 3 SMA patients","volume":"19","author":"Severa","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JND-230197","article-title":"Risdiplam Real World Data - Looking Beyond Motor Neurons and Motor Function Measures","volume":"11","author":"Sitas","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.nmd.2025.105397_bib0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27755","article-title":"Risdiplam for the treatment of adults with spinal muscular atrophy: experience of the Northern Ireland neuromuscular service","volume":"67","author":"McCluskey","year":"2023","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2025.105397_bib0022","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/mus.28327","article-title":"Risdiplam in Adult Patients With 5q Spinal Muscular Atrophy: a Single-Center Longitudinal Study","volume":"71","author":"Gavriilaki","year":"2024","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.nmd.2025.105397_bib0023","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40120-020-00206-3","article-title":"Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy","volume":"9","author":"Trundell","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.nmd.2025.105397_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.770423","article-title":"A Patient-Centered evaluation of meaningful change on the 32-Item motor function measure in spinal muscular atrophy using qualitative and quantitative data","volume":"12","author":"Duong","year":"2022","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.nmd.2025.105397_bib0025","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2016","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.nmd.2025.105397_bib0026","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1111\/ene.14472","article-title":"Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy","volume":"27","author":"Stolte","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.nmd.2025.105397_bib0027","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.apmr.2004.11.049","article-title":"Initial Psychometric assessment of a functional oral intake scale for dysphagia in stroke patients","volume":"86","author":"Crary","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"issue":"10","key":"10.1016\/j.nmd.2025.105397_bib0028","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00415-015-7836-y","article-title":"Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS)","volume":"262","author":"Wada","year":"2015","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.nmd.2025.105397_bib0029","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2753.2010.01513.x","article-title":"The factor structure of the SF-36 in adults with progressive neuromuscular disorders","volume":"18","author":"Banks","year":"2010","journal-title":"J. Eval. Clin. Pract."},{"issue":"5","key":"10.1016\/j.nmd.2025.105397_bib0031","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s11136-013-0565-8","article-title":"Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale","volume":"23","author":"Werlauff","year":"2014","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.nmd.2025.105397_bib0032","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1007\/s12070-024-04484-3","article-title":"Development of a Dutch version of the Sydney Swallow questionnaire: assessing Oropharyngeal Dysphagia Severity in Dutch-Speaking Populations","volume":"76","author":"Audag","year":"2024","journal-title":"Indian J. Otolaryngol."},{"key":"10.1016\/j.nmd.2025.105397_bib0033","article-title":"Development of the SMA independence scale\u2013upper limb module (SMAIS\u2013ULM): a novel scale for individuals with Type 2 and non-ambulant Type 3 SMA","volume":"432","author":"Trundell","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"14","key":"10.1016\/j.nmd.2025.105397_bib0034","doi-asserted-by":"crossref","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nmd.2025.105397_bib0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2025.105397_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121799","article-title":"Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial","volume":"10","author":"Seferian","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.nmd.2025.105397_bib0037","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0038","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","article-title":"Natural history of lung function in spinal muscular atrophy","volume":"15","author":"Wijngaarde","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.nmd.2025.105397_bib0039","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3233\/JND-230248","article-title":"A Systematic Literature Review of the Natural History of Respiratory, Swallowing, Feeding, and Speech Functions in Spinal Muscular Atrophy (SMA)","volume":"11","author":"Mart\u00ed","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2025.105397_bib0040","article-title":"Swallowing function in patients with spinal muscular atrophy before and after the introduction of new gene-based therapies: what has changed?","author":"Ruggiero","year":"2024","journal-title":"Neurol Sci"},{"issue":"2","key":"10.1016\/j.nmd.2025.105397_bib0041","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/JND-221595","article-title":"Patient Reported Outcome Measures in Adult Spinal Muscular Atrophy: a Scoping Review and Graphical Visualization of the Evidence","volume":"10","author":"Slayter","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"10.1016\/j.nmd.2025.105397_bib0042","article-title":"Quality of life in SMA patients under treatment with nusinersen","volume":"29","author":"Mix","year":"2021","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.nmd.2025.105397_bib0043","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1007\/s00415-023-11711-4","article-title":"An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy","volume":"270","author":"Bjelica","year":"2023","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.nmd.2025.105397_bib0044","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.3390\/jcm12103458","article-title":"Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): challenges and Opportunities","volume":"12","author":"Rodriguez-Torres","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.nmd.2025.105397_bib0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180342","article-title":"Perceived Fatigue in Spinal Muscular Atrophy: a Pilot Study","volume":"6","author":"Dunaway Young","year":"2019","journal-title":"J Neuromuscul Dis"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T18:41:36Z","timestamp":1754505696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"alternative-id":["S0960896625001245"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105397","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-year Risdiplam treatment in adults with spinal muscular atrophy: improvements in motor and respiratory function, quality of life and fatigue","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105397"}}